Health
China’s 2nd protein subunit COVID-19 vaccine to enter clinical trials, easy to mass produce – Global Times
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed…
Sinopharm’s COVID-19 vaccine. Photo: VCG
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.
Sinopharm’s vaccine is the second protein subunit vaccine in the country after one developed by China’s Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.
The protein subunit vaccine…
-
Noosa News13 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News19 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General22 hours agoProductivity summit ends day two with progress on rules changes to boost housing supply
-
General24 hours agoRed tape on chopping block in bid to build homes faster